Compare Datadog Inc (DDOG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs IDEXX Laboratories, Inc. — how do they compare? Datadog Inc trades at $293.26 (market cap $98.31B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: Datadog Inc is far larger — about 2.4× IDEXX Laboratories, Inc.'s market cap, and Datadog Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DDOG | IDXX | |
|---|---|---|
Market Cap | $98.31B | $40.43B |
Volume | 2,936,660 | 692,164 |
Sector | Technology | Health |
52-Week High | $288.15 | $766.68 |
52-Week Low | $102.62 | $504.70 |
Typical Hold Time | 76 Days | 46 Days |
Enterprise Value | $94.61B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $293.26, up 8.08% in the last session, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth from $2.7B in 2024 to $3.4B in 2025. Recent news highlights accelerating AI and enterprise customer expansion, with FBN Securities initiating coverage with an Outperform rating.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and accelerating AI-driven growth, though elevated valuation ratios (P/E 547.6, P/S 25.33) pose risks if growth moderates. Key risks include competitive pressure in cloud monitoring and dependence on enterprise spending cycles. The stock trades above the $276.10 consensus target, suggesting near-term upside may be limited despite bullish sentiment.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
